Primary Care Enhanced Services

The NHS Lincolnshire Integrated Care Board is planning to award a contract under the Health Care Services (Provider Selection Regime) Regulations 2023 for the provision of Primary Care Enhanced Services. These include specialised services such as phlebotomy, pessaries, anticoagulation monitoring (Warfarin, DOAC), gonadorelin administration (Zoladex), specialised drug monitoring, and safeguarding. The process utilises a direct award approach without prior competition, and the notice marks the start of a standstill period wherein providers can make representations until 10 September 2025.

The contract, valued at £150,086 for its duration from 1 April 2025 to 31 March 2026, has not yet been formally awarded as this notice signifies an intention to award. This process is in the award stage according to the Provider Selection Regime. This contract represents a valuable opportunity for businesses specialising in healthcare services, particularly those focusing on enhanced primary care.

SMEs that already provide or are capable of providing high-quality general-practitioner services would be well-positioned to compete, especially if they can demonstrate innovation, value for money, and a commitment to service integration and social value. With the NHS seeking to improve access and reduce health inequalities, businesses with strategies aligned with these goals will be at an advantage. The procurement's direct award nature indicates an existing relationship with the Long Sutton Medical Centre, which reflects the buyer's preference for providers with a proven track record of satisfying existing contracts.

This approach provides opportunities for suppliers ready to enhance their collaboration within the healthcare system and further develop their service delivery capabilities.